Australia markets closed

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3500+0.0900 (+7.14%)
At close: 04:00PM EDT
1.3500 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Loading interactive chart…
  • Zacks

    InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

    InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

    InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 INF904 development will be initially targeted at chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), with initiation of a Phase IIa PK dose-ranging study expected by the end of 2024, with data availability anticipated in 2025 InflaRx is considering partnership options for

  • GlobeNewswire

    InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

    JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results